TY  - JOUR
T1  - SEverity of comorbidity and non–prostate cancer mortality in men with early-stage prostate cancer
AU  - Daskivich T, Sadetsky N, Kaplan SH, Greenfield S, Litwin MS
Y1  - 2010/08/09
N1  - 10.1001/archinternmed.2010.251
JO  - Archives of Internal Medicine
SP  - 1396
EP  - 1397
VL  - 170
IS  - 15
N2  - 
Comorbidity is a key consideration in clinical decision making for prostate cancer. Early-stage prostate cancer often follows an indolent course, with the significant survival advantage of definitive local therapy developing at 8 years after treatment.1 Men with severe comorbidity may not live long enough to benefit from aggressive therapy and therefore may prefer to treat their disease conservatively. Unfortunately, the lack of a standardized and practical comorbidity assessment tool has limited the application of comorbidity to clinical decision making in this setting.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2010.251
UR  - http://dx.doi.org/10.1001/archinternmed.2010.251
ER  -